Aim: To determine prospectively from the referring physician's point of view the impact of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) results on the management decisions in patients with known or suspected lung cancer. Methods: Seventy-five consecutive patients (58 men, 17 women; age range, 33-82 years; mean age, 64 years) with a diagnosis of a pulmonary lesion, obtained by means of morphological imaging studies and/or cytological sampling, were included in the study. The patient population consisted of three groups: (A) patients (n = 18) with a solitary lung nodule; (B) patients (n = 37) with untreated lung cancer; and (C) patients (n = 20) with treated lung cancer. All were referred for whole-body 18F-FDG PET within 15 days (mean, 11 days) of lung lesion detection. To determine whether and how PET findings could modify the treatment strategy, a questionnaire was sent to the referring physician before and after the PET results. With regard to the treatment strategy, four major options were recognized: (1) further diagnostic investigations; (2) medical therapy; (3) surgical treatment; (4) wait-and-see. For data analysis, intermodality changes, defined as changes between treatment strategies related to PET findings, were considered. Results: Before the PET study, the planned management for the overall patient population was as follows: further diagnostic investigations in 44 cases (58%), medical therapy in 17 (23%), surgical treatment in nine (12%) and wait-and-see in five (7%). After the PET study, further diagnostic tools were indicated in 27 cases (36%), medical therapy in 17 (23%), surgical treatment in 28 (37%) and wait-and-see in three (4%). Relative to the initially planned strategy, changes in patient management after PET imaging occurred in 34 (45%) cases. Overall, the most relevant variation after PET concerned the surgical treatment strategy. The highest percentage (67%) of changes in management after PET was found in patients with a solitary pulmonary nodule; the percentages of changes of the three patient groups were significantly different (chi-squared test; P = 0.021). Conclusions: In patients with known or suspected lung cancer, 18F-FDG PET results determined significant variations in major clinical management decisions. (copyright) 2005 Lippincott Williams & Wilkins.

Patients with known or suspected lung cancer: Evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study / L. Gianolli, G. Pepe, C. Rossetti, S. Sironi, C. Landoni, P. Zannini, U. Pastorino, F. Fazio, C. Messa, L. Galli, A. Grimaldi, M. Mezzetti. - In: NUCLEAR MEDICINE COMMUNICATIONS. - ISSN 0143-3636. - 26:9(2005), pp. 831-837.

Patients with known or suspected lung cancer: Evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study

L. Galli;M. Mezzetti
2005

Abstract

Aim: To determine prospectively from the referring physician's point of view the impact of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) results on the management decisions in patients with known or suspected lung cancer. Methods: Seventy-five consecutive patients (58 men, 17 women; age range, 33-82 years; mean age, 64 years) with a diagnosis of a pulmonary lesion, obtained by means of morphological imaging studies and/or cytological sampling, were included in the study. The patient population consisted of three groups: (A) patients (n = 18) with a solitary lung nodule; (B) patients (n = 37) with untreated lung cancer; and (C) patients (n = 20) with treated lung cancer. All were referred for whole-body 18F-FDG PET within 15 days (mean, 11 days) of lung lesion detection. To determine whether and how PET findings could modify the treatment strategy, a questionnaire was sent to the referring physician before and after the PET results. With regard to the treatment strategy, four major options were recognized: (1) further diagnostic investigations; (2) medical therapy; (3) surgical treatment; (4) wait-and-see. For data analysis, intermodality changes, defined as changes between treatment strategies related to PET findings, were considered. Results: Before the PET study, the planned management for the overall patient population was as follows: further diagnostic investigations in 44 cases (58%), medical therapy in 17 (23%), surgical treatment in nine (12%) and wait-and-see in five (7%). After the PET study, further diagnostic tools were indicated in 27 cases (36%), medical therapy in 17 (23%), surgical treatment in 28 (37%) and wait-and-see in three (4%). Relative to the initially planned strategy, changes in patient management after PET imaging occurred in 34 (45%) cases. Overall, the most relevant variation after PET concerned the surgical treatment strategy. The highest percentage (67%) of changes in management after PET was found in patients with a solitary pulmonary nodule; the percentages of changes of the three patient groups were significantly different (chi-squared test; P = 0.021). Conclusions: In patients with known or suspected lung cancer, 18F-FDG PET results determined significant variations in major clinical management decisions. (copyright) 2005 Lippincott Williams & Wilkins.
18F-FDG PET; Clinical management; Lung cancer; Lung lesion
Settore MED/21 - Chirurgia Toracica
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/12396
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact